The Global X Brazil Active ETF offers a client friendly structure and looks beyond the benchmark in an attempt to find companies with low leverage. Click to read.

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by 30% and net ...

Rocket Mortgage and Redfin are powerful brands and Dan Gilbert's company insists a streamlined process they plan to create ...

Operator Good morning and welcome to the Signet Jewelers fourth quarter fiscal 2025 earnings call. Please note that this event is being recorded. Joining us today on the call are Rob Ballew, senior ...

In the first quarter of 2024, the Company sold its Evi assets in northern Alberta and certain non-core assets located in the Provost area of Central Alberta. Net proceeds of approximately CAD$24.2 ...

Operator Greetings and welcome to the 3D Systems fourth quarter and fiscal year 2024 earnings conference call and webcast. At ...

Southern Cross Gold Consolidated Ltd. announces a drilling and geophysical exploration activity update. Two further diamond drill rigs will mobilize to Sunday Creek next week to increase the total ...

Adjusted EBITDA, a non-GAAP financial measure (discussed in greater detail below), increased 31% to $22.9 million in 2024, compared to $17.5 million in 2023. Reported revenue of $39.6 million, ...

GOOSE CREEK, SC / ACCESS Newswire / March 27, 2025 / HireQuest, Inc. (Nasdaq:HQI), a national franchisor of direct dispatch, executive search, and commercial staffing services, today reported financia ...

The Board unanimously recommends shareholders vote against this resolution on the basis that: The remainder of this statement provides a summary of the Board's position, with further detail in the ...

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and EMA marketing authorizations ...